Fed Governor Adriana Kugler to resign
In a turbulent market environment, GYRE stock has faced significant headwinds, with shares currently trading at $6.46, just slightly above its 52-week low of $6.17. InvestingPro analysis indicates the stock is trading below its Fair Value, suggesting potential upside opportunity. This latest price level reflects a stark contrast to the stock's performance over the past year, with Targacept (NASDAQ:GYRE), GYRE's parent company, witnessing a substantial decline of 57.41%. Despite the downturn, the company maintains strong fundamentals with a healthy current ratio of 3.32 and robust liquidity position. Investors are closely monitoring the company's strategic moves and market conditions, as the stock grapples with market volatility and industry-specific pressures. InvestingPro subscribers have access to 10 additional key insights about GYRE's financial health and valuation metrics.
In other recent news, Gyre Therapeutics reported fourth-quarter revenue of $27.87 million, marking a slight increase from the previous year's $27.1 million. The company also provided a full-year 2025 revenue guidance of $118 million to $128 million, which falls short of the $135.7 million anticipated by analysts. This guidance accounts for the commercial launches of two new products, nintedanib for idiopathic pulmonary fibrosis and avatrombopag for chronic liver disease-associated thrombocytopenia, expected to begin selling in China this year. Additionally, Gyre Therapeutics has received approval from China's National Medical (TASE:BLWV) Products Administration to start a clinical trial for pirfenidone, targeting radiation-induced lung injury and checkpoint inhibitor pneumonitis.
The company plans to implement an adaptive Phase 2/3 clinical trial design for this purpose. Furthermore, Gyre Therapeutics has advanced its Phase 3 trial on hydronidone for liver fibrosis in chronic hepatitis B patients, having completed patient enrollment in October 2024. The trial protocol has been published in the Journal of Clinical and Translational Hepatology, with topline results expected in the second quarter of 2025. Gyre Pharmaceuticals, the parent company, reported 2024 net sales of $105.8 million for its flagship product, ETUARY, which was the first approved treatment for idiopathic pulmonary fibrosis in China.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.